Riskpilot← Back to searchSign inGet full accessLångängen Pharma AB
ABDissolvedOrg 5590917992Economic activity was not specified by tax authority · NACE 0000Est. 20160 employees
Revenue 2021
SEK 0
EBITDA margin
—
0% vs 2020
Equity ratio
36.7%
Financial strength
Net profit 2021
SEK 22,4M
+40% vs 2020
| Revenue | SEK 0 | — |
| EBITDA | SEK -3K | +0% |
| Net profit | SEK 22,4M | +40% |
| Total assets | SEK 61,2M | +37% |
| Equity | SEK 22,5M | +37% |
| Employees | 0 | — |
Legal name
Långängen Pharma AB
Org number
5590917992
Legal form
Aktiebolag
NACE code
0000 · Economic activity was not specified by tax authority
Founded
16 december 2016
Share capital
SEK 0
Employees
0
VAT registered
No
Audit selected
No
Last report
2021-12-31
Financial year
January – December
Company purpose
Bolaget ska bedriva holdingverksamhet och kapitalförvaltning samt indirekt, via dotterbolag, bedriva verksamhet inom tillverkning och försäljning av läkemedel samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −12 | −3 | −4 | −3 | −3 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −12 | −3 | −4 | −3 | −3 |
| Net financials | −220 | 7 868 | 8 956 | 15 805 | 22 185 |
| Profit before tax | −3 | 8 104 | 8 953 | 16 000 | 22 400 |
| Tax | −0 | −0 | −97 | −0 | −0 |
| Net profit | −3 | 8 104 | 8 856 | 16 000 | 22 400 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Total assets | 12 082 | 20 412 | 28 670 | 44 570 | 61 248 |
| Equity | 47 | 8 151 | 8 907 | 16 407 | 22 451 |
| Long-term debt | 11 805 | 11 805 | 0 | 0 | 0 |
| Short-term debt | 230 | 456 | 19 763 | 28 163 | 38 797 |
| Total debt | 12 035 | 12 261 | 19 763 | 28 163 | 38 797 |
EBITDA margin
-300000.0%
This company
15.8%
Market median
-1898834% vs market
20172021
Equity ratio
36.7%
This company
38.2%
Market median
+4% vs market
20172021
Return on equity
99.8%
This company
18.4%
Market median
+442% vs market
20172021
Net profit margin
2240000000.0%
This company
8.1%
Market median
+27654320888% vs market
20172021
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20172021
Debt / equity
1.73×
This company
0.62×
Market median
-179% vs market
20172021
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-12-01 – 2017-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
RN Chief Auditor | Chief Auditor | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Chairman | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Weflan AB | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Rosemed Holding AB
Långängen Pharma AB Board members of Långängen Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rolf Nicklas Kullberg | Chief Auditor | 0 companies |
| Said Richard Karroum | Board of Directors | 0 companies |
| Ulrika Elisabeth Marie Håkansson | Board of Directors | 0 companies |
| Francois Alexander Karroum | Deputy Board Member | 0 companies |
| Anders Leif Håkansson | Chairman | 0 companies |